Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PAS.0000000000002203 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TFE3 -rearranged Head and Neck Neoplasms : Twenty-two Cases Spanning the Morphologic Continuum Between Alveolar Soft Part Sarcoma and PEComa and Highlighting Genotypic Diversity.
Am J Surg Pathol
November 2024
Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Prague.
TFE3 rearrangements characterize histogenetically, topographically, and biologically diverse neoplasms. Besides being a universal defining feature in alveolar soft part sarcoma (ASPS) and clear cell stromal tumor of the lung, TFE3 fusions have been reported in subsets of renal cell carcinoma, perivascular epithelioid cell tumor (PEComa), epithelioid hemangioendothelioma and ossifying fibromyxoid tumors. TFE3 -related neoplasms are rare in the head and neck and may pose diagnostic challenges.
View Article and Find Full Text PDFSinonasal Melanotic PEComa With NONO::TFE3 Fusion : A Case Report and Letter to the Editor.
Am J Surg Pathol
May 2024
Department of Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.
Virchows Arch
August 2023
Department of Biopathology, Institut Bergonié, Bordeaux, France.
Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 "negative" (0% positive cells); 1+ (1-25% positive cells); 2+ (26-50% positive cells); 3+ (51-75% positive cells), and 4+ "diffuse" (> 75% positive cells).
View Article and Find Full Text PDFNeuroectodermal tumours of the sino-nasal tract: a clinicopathological study of 18 cases with a newly proposed revised classification and a brief review of literature.
Eur Arch Otorhinolaryngol
March 2022
Radiotherapy, JIPMER, Pondicherry, India.
Article Synopsis
- Sino-nasal tract tumours, accounting for 3% of head and neck malignancies, include various rare neuroectodermal tumours such as Ewing's sarcoma and olfactory neuroblastoma, which can be challenging to diagnose due to their overlapping characteristics.
- A study analyzed 18 cases of these tumours collected from 2016 to 2020, with nasal obstruction being the most common symptom, and significant findings noted for metastasis and recurrence rates among different tumour types.
- The research emphasizes the importance of pathologists recognizing subtle morphological and immunohistochemical differences in diagnosing these tumours, as they require distinct treatment approaches and have varying prognoses.
Observed progression from melanosis with melanocyte hyperplasia to sinonasal melanoma with distant metastasis and a unique genetic rearrangement.
J Cutan Pathol
July 2021
Pathology Service, Dermatopathology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Melanosis, clinically presenting as a benign macular hyperpigmentation, consists of increased pigmentation (melanotic or melanocytic) either in the mucosal epithelial cells or as subepithelial pigment-laden macrophages. On the other hand, primary sinonasal mucosal melanoma (SNMM) is a rare disease with poor prognosis and high rates of local recurrence and metastasis. We report follow-up on a previously presented case of a 53-year-old man with recurrent clinical melanosis that progressed from histopathological melanocytic hyperplasia to melanoma in situ over a period of 4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!